Stocktwits36d agobullish
Why Did MRNA, MRK, TGT Stocks Jump To 52-Week Highs Today?Moderna, Merck and Target stocks soared to annual highs amid positive company catalysts and strong earnings results.
Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
141last 24h
863last 7d
142● bullish (7d)
96● bearish (7d)
214publishers
Benzinga36d agobearish
Elon Musk Says mRNA Has 'Tremendous Promise,' Turning Disease Into a 'Software Problem,' as Moderna Stock Rockets 177% on Cancer Vaccine BreakthroughElon Musk said Wednesday that mRNA technology could fundamentally change how diseases are treated, a shift that would make medicine more of a software problem than a biological one, as Moderna Inc. (NASDAQ:MRNA) and Merck & Co Inc. (NYSE:MRK) posted a major cancer-vaccine trial win. mRNA Has ‘Tremendous’ Potential “Despite its obvious misuse during Covid, mRNA has tremendous promise for curing diseases,” Musk said in a post on X. “Artificial RNA essentially makes curing diseases a software probl
Stocktwits36d agoneutral
Dow, S&P 500, Nasdaq Futures Climb As Treasury Yields Pull Back: MRNA, BULL, MSTR, NVAX Stocks In FocusThe U.S. Treasury Department unexpectedly announced Wednesday that it would at least double government debt buybacks, expected to take effect Sept. 9.
Stocktwits36d agobullish
Moderna Is Now S&P 500’s No. 2 Stock This Year — Wall Street, Jim Cramer And Elon Musk Cheer Cancer Vaccine BreakthroughThe breakthrough sparked a broad biotech rally, lifting Merck, BioNTech, Arcturus, cancer-treatment developers, gene-editing stocks and biotech ETFs.
Reuters36d agobullish
Analysis-Moderna, Merck breakthrough could usher in wave of cancer vaccinesCHICAGO, Aug 19 () - Merck and Moderna's success with a personalized cancer vaccine designed to keep melanoma at bay opens a new avenue of treatment that doctors hope will work against many types of tumors. Unlike chemotherapy, which kills both healthy and cancerous cells, or immunotherapy, which revs up the immune system, personalized cancer vaccines train the immune system to specifically target mutations found only on a person's tumor.
Motley Fool36d agoneutral
Why Moderna Stock Skyrocketed TodayThe biotech could be on the verge of setting a new standard of care for skin cancer.
Barrons.com36d agoneutral
Review & Preview: Good MedicinePromising news from a major drug company, reports of some dovish Fed committee members, and a government bond buyback announcement combined forces to boost markets on Wednesday. The S&P 500 and the Nasdaq Composite also closed up 0.2%. The Treasury Department’s announcement this morning also helped calm the bond market—though for how long remains to be seen after the U.S. debt crossed a $40 trillion threshold on Wednesday.
StockStory36d agoneutral
Why Pfizer (PFE) Stock Is Trading Up TodayShares of global pharmaceutical company Pfizer (NYSE:PFE) jumped 3.8% in the afternoon session after positive clinical trial results from peers Merck and Moderna for an mRNA cancer treatment lifted sentiment across the pharmaceutical sector.
Reuters Videos36d agoneutralVIDEO
Why this mRNA cancer vaccine is raising new treatment hope<body><p>STORY: :: Why Moderna and Merck's cancer vaccine trial may be a milestone</p><p>:: New York / August 19, 2026</p><p>:: Michele Gershberg, Global Health Editor</p><p>"The two drugmakers, Moderna and Merck, gave an overview of a clinical trial that was testing a new cancer vaccine, together with a widely used cancer treatment from Merck called Keytruda. It was testing it in melanoma patients, and, it was a large trial. And they said that what they found is that it works better than just Keytruda by itself, when it comes to preventing the disease from returning, or from spreading to other parts of the body." //</p><p>"The trial itself was looking at patients who had just had their tumors removed surgically. // </p><p>At the moment, Moderna has told us that they expect that there are thousands of patients who could benefit from this if they receive regulatory approval. And that approval, their aim is to get it sometime in 2027." //</p><p>"This is designed to treat melanoma. But there are dozens of studies looking at this and all kinds of cancers. In lung cancer, in pancreatic cancer, colon cancer, a wide array. So this is the first sign, scientifically, that, in a large setting, compared to other kinds of treatment, that this works." //</p><p>"The news is extremely significant for Moderna. Our readers may know Moderna as the maker of a very effective COVID-19 vaccine. And they're, you know, their fortunes surged on that vaccine, you know, during and immediately after the pandemic. But since then, use of the vaccine has slowed. // And the idea of a of a cancer vaccine based on its mRNA technology, has attracted a lot of interest.The news today signals that there is more evidence to think that that hope will materialize, and it will become a big marketplace." //</p><p>"The results are also a real positive for Merck. You know, they are very well known for Keytruda for cancer patients. They are testing this vaccine approach in a number of different trials. So it opens up a new possibility for Merck, and it's, you know, in its own therapy. And that is significant because the patent on that, on Keytruda is expected to expire within or later in this decade. And, you know, and this is, you know, opening up their market for them."</p><p>The companies tested the vaccine together with Merck's immunotherapy drug Keytruda, a widely used melanoma treatment. Thousands of patients who have undergone surgery to remove high-risk melanoma tumors could benefit as soon as next year if regulators approve the vaccine, Moderna President Stephen Hoge said in an interview.</p><p>This is the first positive late-stage trial result for an mRNA cancer vaccine, which trains a patient's immune system to fight tumors by targeting specific mutations in those cells, and the first such study to show that adding a treatment to Keytruda worked better than that therapy alone. Merck, Moderna and other companies are testing similar approaches against lung, breast and pancreatic cancers.</p></body>
Reuters Videos36d agoneutralVIDEO
Wall St rises as yields ease, Moderna lifts healthcare stocks<body><p>VIDEO SHOWS: n/a</p><p>STORY: Wall Street's main indexes closed modestly higher on Wednesday, with the Dow, S&P 500 and the Nasdaq all adding less than a quarter of a percent.</p><p>Risk appetite got a boost from easing government bond yields. The yield on the 30-year Treasury bond fell a day after hitting its highest level since 2007. The 10-year Treasury yield also fell. The moves came after the U.S. Treasury announced it would double the size of liquidity support buyback operations for longer-dated bonds.</p><p>Adam Coons is chief investment officer at Winthrop Capital Management.</p><p>"Stocks are, you know, marginally up today. And that's really just driven by the digestion of this yield curve control. You're seeing interest rates come down, in particular long end (long-term rates) quite a bit. And so you're probably going to see markets try to use their crystal ball to determine what's coming next. And so I would expect volatility. Today seems like a day of rest to some degree. But I would say that volatility and increased volatility heading into, you know, changes in Fed policy should be the new expectation."</p><p>Investors, however, barely reacted to minutes from the Federal Reserve's July meeting, which showed deepening concern about inflation with "several" policymakers ready to raise interest rates. "Many" said a rate hike would be needed if inflation does not lower to the central bank's 2% target.</p><p>:: Archive</p><p>Stocks on the move Wednesday included Moderna which surged almost 177% after the company said its personalized mRNA cancer therapy developed with Merck cut the risk of melanoma recurrence and spread in a late-stage trial. Merck shares also jumped about 12.5% and it was the biggest gainer in the Dow.</p><p>::Marvell Technology</p><p>Shares of Marvell Technology climbed nearly 10% after the company said it will help develop Google's in-demand custom chips and has offered the search giant the right to buy a potential $12.2 billion stake.</p><p>And shares of Target rose more than 4% after the retailer raised its annual sales forecast. Lowe's shares gained even after it trimmed its annual sales growth forecast and Estée Lauder shares jumped more than 16% after the cosmetics maker forecast annual profit above Wall Street estimates.</p></body>
Insider Monkey36d agoneutral
Moderna (MRNA)’s Melanoma Vaccine Win: Big Opportunity, Bigger ExpectationsModerna, Inc. (NASDAQ:MRNA) has delivered a major boost to its turnaround story. Its personalized mRNA cancer vaccine, Intismeran, met the main goal of reducing melanoma recurrence and also showed a benefit in preventing the cancer from spreading when used with Merck’s Keytruda. The result is especially important because it is the first positive late-stage trial […]
StockStory36d agoneutral
Novavax (NVAX) Shares Skyrocket, What You Need To KnowShares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 6.9% in the afternoon session after positive trial results from peers Moderna and Merck for their personalized cancer vaccine boosted sentiment across the vaccine sector.
The Wall Street Journal36d agobullish
Moderna Stock Soars on Cancer Vaccine Success1. Moderna shares more than doubled after it reported successful results in an experimental mRNA-based cancer vaccine. The company and its partner Merck reported this morning that the vaccine succeeded in preventing cancer from coming back or spreading in a study of high-risk melanoma patients. The positive results sent Moderna’s share price soaring and rippled through drug industry stocks as investors saw the potential for more future blockbusters.
StockStory36d agoneutral
Why Is Moderna (MRNA) Stock Rocketing Higher TodayShares of biotechnology company Moderna (NASDAQ:MRNA) jumped 144% in the afternoon session after its personalized mRNA cancer vaccine, developed with Merck, met key goals in a late-stage trial.
Yahoo Finance Video36d agoneutralVIDEO
Moderna, Merck melanoma cancer vaccine is a 'grand slam': Dr. Ezekiel EmanuelDr. Ezekiel Emanuel sits down with Julie Hyman to discuss the late-stage trial results of the new mRNA cancer treatment vaccine being tested by Moderna (MRNA) and Merck (MRK). Dr. Emanuel was an advisor to President Obama and a member of the Biden-Harris Transition COVID-19 Advisory Board.
Barrons.com36d agobullish
Stocks Hitch a Ride on the Bond Market's RallyThe stock market rode the bond market's coattails en route to its first gain in four sessions. The Nasdaq Composite gained 0.2%. News that the Treasury Department will at least double the size of buyback operations for longer-duration bonds sent bond prices rallying.
MT Newswires36d agoneutral
Sector Update: Healthcare Stocks Gain Late AfternoonHealthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index rising 3.1% a
Stocktwits36d agoneutral
SLS Stock Edges Higher As Wall Street, Retail Expect Another MRNA MomentMaxim Group described Moderna’s positive late-stage melanoma results as a “win for cancer vaccines,” arguing the surge in Moderna shares should support SELLAS if its key trial succeeds.
Barrons.com36d agobullish
BioNTech Stock Surges 20% on Moderna Cancer Vaccine Win. Why the Gains Could Fade.BioNTech, a former pioneer of mRNA cancer vaccines, was part of a broad rally Wednesday. Leerink analysts don’t expect the momentum to last.
24/7 Wall St.36d agobullish
Moderna’s Cancer Breakthrough Just Made Tempus AI’s $1.5 Billion Bet Look BrilliantTempus AI wrote a $1.5 billion check for a genomics company most investors had never heard of, and one blockbuster clinical trial announcement just changed everything about how that deal looks.
The Wall Street Journal36d agoneutral
mRNA Vaccine Stocks Rise on Moderna-Merck SuccessDrug company stocks soared following news that Moderna and Merck’s experimental mRNA-based cancer vaccine succeeded in a late-stage trial at preventing melanoma from returning or spreading. The S&P health-care sector is on track for an all-time closing high, as is Merck, according to data that goes back to 1972. As of Wednesday afternoon, Moderna’s stock had more than doubled, something that a member of the S&P 500 hasn't done in a single day since 2008, according to Dow Jones Market Data.
MT Newswires36d agoneutral
Top Midday GainersZeroStack (ZSTK) said Wednesday it entered a $1 billion crypto contribution agreement that will add
Barrons.com36d agoneutral
Moderna Could Be First S&P 500 Stock Since 2008 to Double in a DayModerna’s cancer vaccine breakthrough has the stock on track to do something that hasn’t been done since 2008. The stock was up 141% on Wednesday, putting it on track to be the first S&P 500 company to rise 100% or more in a day since Dec.
GuruFocus.com36d agobullish
Merck Surges 7.5% After First Phase 3 mRNA Cancer-Vaccine WinA successful melanoma trial could extend Keytruda's growth story beyond conventional immunotherapy.